Homoharringtonine and granulocyte colony-stimulating factor priming for acute myeloid leukemia: is it ready for prime time?

Chen and colleagues [1] in the current issue of Leukemia and Lymphoma have investigated a combination of homoharringtonine (HHT), aclarubicine, cytarabine and granulocyte colony-stimulating factor (G-CSF) (CHAG) in treating 36 patients (aged 16 – 61 years) with relapsed (19%) or refractory (67%) acute myeloid leukemia (AML) [2]. HHT was given at 1 mg/m 2 intravenously (IV) from day 1 to day 14. Complete remission (CR) was achieved in 81% and partial remission (PR) in 14% of the patients. Th e median duration to neutrophil recovery was 15 days. Cardiac toxicity was not noted in this study. One patient had liver dysfunction that spontaneously improved. Th e results are encouraging, with an excellent response rate that exceeds the expected 17 – 60% response rate for conventional therapies used in this setting [3 – 9]. However, longer follow-up and ultimately randomized trials are warranted to assess the actual eff ect of this or other combinations. In the early 1970s, HHT and other ester alkaloid cephalotaxins were isolated from the bark of the Cephalotaxus fortunei evergreen tree and found to have activity against murine leukemia by decreasing protein synthesis and inducing apoptosis [10 – 12]. In one of the earliest Chinese studies, mixtures of HHT and harringtonine (HT) at diff erent dosing schedules (IV or intramuscular [IM]) led to fi ve CRs in 41 evaluable patients (12%). Th e study indicated that the maximum tolerated therapeutic eff ective dose was 4 mg daily IV for 14 days. Major dose-limiting toxicities were myelosuppression and cardiovascular abnormalities, including hypotension and arrhythmias [13]. More Chinese phase I and II studies were summarized by Grem et al . [14] in a landmark article that showed a CR rate of 24% (65 of 274 patients) in patients with AML. As HHT is a G1/G2-phase specifi c drug that causes leukemic cell transformation into S-phase [15], this provided the theoretical basis to combine it with other agents that are S-phase specifi c such as cytarabine [16,17]. In 1980, the HOAP (HHT, vincristine, cytarabine and steroids) regimen resulted in CRs in 82% (23/28) of newly diagnosed patients with AML [18], but with more profound myelosuppression and cardiac toxicities. Similarly, HHT in combination with cytarabine and thioguanine was used in newly diagnosed patients with AML, resulting in a CR rate of 68% [19]. The success of the Chinese studies motivated US investigators to use HHT in acute leukemias. In 1984, the first US phase I trial by Legha et al . [20] investigated HHT daily bolus infusion over 10 – 360 min for 1 – 10 days, with dose escalation 0.2 – 8 mg/m 2 daily in 43 patients with advanced malignancies, including five patients with acute leukemia; CR was achieved in three of the five patients. Hypotension was the limiting toxicity for doses 4 mg/m 2 daily. Other phase I bolus studies showed similar results and recommended a phase II dose of 3 – 4 mg/m 2 daily for 5 days as a short infusion [21]. Since hypotension seemed to be related to vasodilatation following the bolus infusion, HHT was administered through continuous infusion (CIVI). In a phase I – II study, Warrell et al . [22] used CIVI HHT in 49 patients with relapsed or refractory AML and concluded that dosing at 5 mg/m 2 daily for 9 days is a reasonable option, as any higher doses caused significant hypotension as in the bolus schedule. CR was achieved in 25% of the patients (consisting of both relapsed and refractory AML) and lasted for a median of 6 months. HHT CIVI was also effective in myelodysplastic syndrome (MDS) and MDS transformed to AML as shown by Feldman et al . [23], where eight of 28 patients responded, but early death due to neutropenic complications was seen in 46%. Myelosuppression was an issue with CIVI, as full bone marrow recovery took up to 24 days. Subcutaneous (SQ) HHT was first used in a phase I trial in 2006 when Levy et al . [24] treated 18 adults patients with relapsed/refractory AML, accelerated myeloproliferative neoplasms or refractory MDS with dose-escalated twice-daily SQ HHT 0.5 – 6 mg/ m 2 for 9 days. The study defined a maximum tolerated dose as 5 mg/m 2 daily, resulting in two CRs in patients with AML (lasting 3 and 4 months) and hypoplastic bone marrow on day 10 in five of 14 patients, in addition to clearing peripheral blasts. Adverse events included hyperglycemia, fluid retention and infectious complications.